IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Phase 1
Completed
- Conditions
- Lymphoma, Non-HodgkinChronic Lymphocytic Leukemia
- Interventions
- Registration Number
- NCT01534715
- Lead Sponsor
- ImmunoGen, Inc.
- Brief Summary
The purpose of this study is to test the safety and tolerability of IMGN529 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 49
Inclusion Criteria
- Relapsed or refractory NHL including tumor types: Follicular lymphoma (FL), marginal zone lymphoma (MZL)/mucosa-associated lymphoid tissue (MALT), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL).
- Adequate organ function
- ECOG ≤ 2
- Recovered or stabilized from prior treatments.
Exclusion Criteria
- Allogeneic stem cell transplantation
- Pregnant or lactating females
- Known central nervous system, meningeal or epidural disease including brain metastases
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description IMGN529 IMGN529 Dose escalation study, dosing done every 3 weeks.
- Primary Outcome Measures
Name Time Method Occurrence of dose limiting toxicities During study
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (7)
Memorial Sloan-Kettering Cancer Center
🇺🇸New York, New York, United States
Medical College of Wisconsin
🇺🇸Milwaukee, Wisconsin, United States
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
CTRC at UTHSCSA
🇺🇸San Antonio, Texas, United States
Ohio State University
🇺🇸Columbus, Ohio, United States
Sarah Cannon Research Institute
🇺🇸Nashville, Tennessee, United States
Oncology Institute of Southern Switzerland
🇨🇭Bellinzona, Switzerland